ÂÜÀòÂÒÂ×

John Kurek has over 20 years of experience in the biotechnology industry. John began their career in 1998 as Preclinical Development Manager at Amrad Corporation (Zenyth Pharmaceuticals) Ltd. In 2003, they moved to Biodiem Ltd as Pharmaceutical Development Manager, where they were responsible for managing the preclinical, clinical and regulatory aspects of drug development programs. In 2012, they began their role as Non Executive Director at Q-Sera Pty Ltd. John then took on Non Executive Director roles at OccuRx in 2013, Axelia Oncology Pty Ltd (Formally Ena Therapeutics) in 2016, EXONATE LIMITED in 2016, Kinoxis Therapeutics Pty Ltd in 2018, Certa Therapeutics in 2018, and Ena Respiratory Pty Ltd in 2020. In 2007, they became Investment Manager at Uniseed, Australia's longest-running venture fund.

John Kurek's education history includes completing a Graduate, Company Directors Course at the Australian Institute of Company Directors in 2007, a Graduate Diploma in Drug Evaluation & Pharmaceutical Science at the University of Melbourne in 1997-1998, a PhD in Neuroscience at the University of Melbourne from 1993-1996, a BSc (Hon) in Biochemistry at Monash University from 1985-1988, and an HSC in 1984.